Holen Sie sich die Stockscreener-App
4.53
2.16%
-0.10
Vorhandelsmarkt:
4.40
-0.13
-2.87%
Schlusskurs vom Vortag:
$4.63
Offen:
$4.58
24-Stunden-Volumen:
7,541
Relative Volume:
0.01
Marktkapitalisierung:
$6.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.49M
KGV:
-0.1529
EPS:
-29.6295
Netto-Cashflow:
$-15.24M
1W Leistung:
-1.74%
1M Leistung:
-8.48%
6M Leistung:
-34.51%
1J Leistung:
-54.46%
1-Tages-Spanne:
$4.5265
$4.58
1-Wochen-Bereich:
$4.4012
$5.10
52-Wochen-Spanne:
$1.90
$12.36
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Firmenname
Cns Pharmaceuticals Inc
Sektor
Branche
Telefon
1-800-946-9185
Adresse
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
4.53 | 6.93M | 0 | -16.49M | -15.24M | -29.63 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | Eingeleitet | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Aktie (CNSP) Neueste Nachrichten
Why did CNSP stock surge 330% today? - MSN
CNSP Q1 2026 Earnings: Wider Than Expected Loss, No Revenue Reported; Stock Rises 3.6%Estimate Revision Count - newsline.com
CNS Pharmaceuticals (CNSP) Tests Key Levels After Modest GainBreadth Thrust - newsline.com
Relmada Therapeutics Appoints CNS Drug Development Veteran - GlobeNewswire
CNS Pharmaceuticals Company Profile & Introduction - Moomoo
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor Presentation - TradingView
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-than-Expected Loss Highlights Cash Burn and Pipeline ChallengesPretax Income Report - newsline.com
CNS Pharmaceuticals Highlights Oversubscribed $22.5 Million Financing and Growth Strategy - citybuzz -
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment - ACCESS Newswire
Biotech CFO breaks down oversubscribed $22.5M raise and strategy shift - Stock Titan
NRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS Therapeutics - Quiver Quantitative
CNS Pharmaceuticals (CNSP) Shows Resilience with 2% Gain, Testing Key ResistanceSeasonality Effect - newsline.com
CNSP Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Quality Score - newsline.com
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Pipeline Advances - newsline.com
CNS Pharmaceuticals Surges 11% as Biotech Sector Shows Renewed InterestDeath Cross - The Legal Advocate
CNS Pharmaceuticals (CNSP) Faces Selling Pressure as Shares Decline Over 5%Total Put Call - The Legal Advocate
CNS (CNSP) Suffers -4.49% Decline on Heavy Selling 2026-05-28Initial Balance - newsline.com
Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight - GlobeNewswire Inc.
[EFFECT] CNS Pharmaceuticals, Inc. SEC Filing - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) registers 9.79M resale shares from May private placement - Stock Titan
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress - Bluefield Daily Telegraph
Insider Buying: Faith Charles Acquires Shares of CNS Pharmaceuti - GuruFocus
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock By Investing.com - Investing.com Canada
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock - Investing.com
CNSP | CNS Pharmaceuticals, Inc. Common Insider Trading - Quiver Quantitative
CNS Pharmaceuticals raises $22.5M to advance new biotech therapies and strategic growth. - Pluang
[Form 4] CNS Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
CNS Pharmaceuticals Registers 9.79 Million Shares for Selling Holders - Moomoo
CNS Pharmaceuticals (CNSP) registers 9.79M shares including prefunded warrants - Stock Titan
cns pharmaceuticals inc Earnings dates - RTTNews
NRXP: Advanced CNS drug pipeline, reduced net loss, and expanded clinical footprint in Q1 2026 - TradingView
CNS Pharmaceuticals, Inc. announced that it has received $22.515858 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Nazare Partners and other investors - marketscreener.com
Stonepine (CNSP) reports 159,790 shares; 9.9% position disclosed - Stock Titan
Maxim Group Maintains CNS Pharmaceuticals(CNSP.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Addex Therapeutics (ADXN.SW) Jumps 6.7% as CNS Drug Pipeline Advances - Meyka
CNSP Poised for Growth Through Strategic Initiatives - GuruFocus
CNS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CNSP's Financial Outlook After Recent Fundraising - GuruFocus
CNS Pharmaceuticals, Inc. Q1 2026 Financials and Corporate Strategy Update – 10-Q Report Highlights - Minichart
CNS Pharmaceuticals : CNSP - 24/7 Wall St.
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transforma - PharmiWeb.com
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress - ACCESS Newswire
Biotech CNS Pharmaceuticals secures $22.5M to buy neurology, oncology drugs - Stock Titan
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CNS Pharmaceuticals (CNSP) widens Q1 loss but secures $22.5M private placement - Stock Titan
ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus - AD HOC NEWS
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6 - 24/7 Wall St.
TradingKey - TradingKey
CNS Pharmaceuticals Inc expected to post a loss of $5.37 a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Finanzdaten der Cns Pharmaceuticals Inc-Aktie (CNSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):